Plethori Partners with ClinTex and Previews a Real Use Case ETF
Plethori is proud to announce their latest partnership with blockchain and clinical intelligence company, ClinTex. The partnership will see ClinTex’s token - CTI - approved as one of the underlying assets in Plethori’s V1 megatrend ETFs, and involve both partners in mutually beneficial cross-promotional activities, and cross-pollination of ideas.
ClinTex are providing a solution to the gross economic inefficiencies of the pharmaceutical industry with their groundbreaking platform, CTi — Clinical Trials Intelligence. CTi is a distributed technology platform that incorporates predictive data analytics, machine learning (AI), and the innovative use of smart contracts to drive significant quality and operational improvements in clinical trials.
Applying the blockchain and smart contracts to the real use case of clinical trials, ClinTex’s CTi is assured to drive down the cost of medicine. Such a sorely needed solution to skyrocketing medical costs, ClinTex was chosen by Plethori for its true-to-crypto spirit of improving the world through DeFi technologies.
CEO Callum Mitchell-Clark commented on the partnership: “It feels great to be partnering with such a philanthropic yet practically useful project as ClinTex. The real-world benefits they offer are sure to be recognised and valued across the crypto industry, as well as beyond it, and that is why we are choosing ClinTex as one of the underlying assets for our V1 megatrend ETFs. The most suitable of our impressive roster of megatrend ETFs would be our ‘real use case’ ETF, currently in planning. It will offer investors an unprecedented opportunity to invest in blockchain technologies with practical applications to solve real-world problems. Something investors have been crying out for since the advent of the blockchain era.”
Real Use Case ETF
Plethori’s real use case ETF will consist of a curated selection of assets selected for having real use cases such as data sharing, royalties tracking, supply chain logistics, personal identity security, and voting mechanisms, among others. Investors expecting growth in the pragmatic and real-world applications of blockchain technology will finally have an investment vehicle with which they can expose themselves to a diversity of investments, buying into the entire sector with just a single transaction, on Plethori’s upcoming ETF Exchange platform, the ETFX.
As with all the megatrend ETFs, Plethori’s native PLE token will constitute 5% . This creates constant deflationary pressure on the token supply, exposing PLE to higher forces of demand as ETFs are purchased on the ETFX. Holders of PLE are also granted privileges, such as access to the ETF creation portal, ETF whitelists, and a 25% discount on fees.
For the latest news from Plethori, including strategic partnership announcements, product updates and much more, sign up for the newsletter now and follow Plethori on Telegram and Twitter.
About ClinTex
ClinTex are pioneering a new software platform — Clinical Trials Intelligence (CTi) — aimed at transforming the medicine development industry. ClinTex’s mission is to bring down the cost of medicine through predictive analytics, machine learning, and the novel use of blockchain technology and smart contracts in clinical trials. ClinTex’s CTi will improve the speed-to-market of new medicines for the people who need them, through vastly reducing development costs.
Website | Telegram | Twitter | Medium | Whitepaper
About Plethori
Plethori is a Crypto ETF creation and trading protocol that allows users to invest in a wide range of Crypto ETFs comprising assets from sectors driving the crypto space. Plethori’s ETFX provides the framework for users to create and manage customised ETFs, earning a percentage of the transaction fees each time their fund is traded.
Offering the world’s most popular financial product within an innovative and gamified platform, Plethori are focused on facilitating mass adoption and accelerating the decentralisation of the global economy.
Website | Telegram | Twitter | Whitepaper
